Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $177.00.

A number of equities analysts have recently weighed in on JAZZ shares. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. TD Cowen cut their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th.

Jazz Pharmaceuticals Trading Up 0.5 %

Shares of JAZZ stock opened at $123.76 on Friday. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business’s fifty day moving average price is $120.81 and its 200 day moving average price is $113.63. The firm has a market capitalization of $7.48 billion, a PE ratio of 17.43, a P/E/G ratio of 1.04 and a beta of 0.57.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,753 shares of company stock worth $816,289 in the last three months. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Jazz Pharmaceuticals by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 130 shares in the last quarter. Coldstream Capital Management Inc. grew its position in Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after acquiring an additional 165 shares during the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.